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Nicotine is an alkaloid obtained from the leaves of the tobacco plant, and it is the main constituent of 
tobacco smoke. This review opens with physical and chemical properties of nicotine and with general 
considerations about the methods for determining nicotine and its metabolite cotinine. It summarises the 
data about acute and long-term toxicity of nicotine and also reviews its metabolism and kinetic data, types 
of exposure and the main recognised health effects, with special attention to reproductive, cardiovascular, 
pulmonary, gastrointestinal, immunological and genetic toxicity. The main focus is on hazardous exposure
and risk estimation.
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Nicotine is a naturally occurring alkaloid found 
primarily in the members of the Solanaceae family, 
which includes tobacco, potato, tomato, green 
pepper, and eggplant. Nicotine was first isolated and 
determined to be the major constituent of tobacco 
in 1828 (1). In commercial tobaccos, the major 
alkaloid is nicotine, accounting for about 95 % of the 
total alkaloid content (2). Tobacco use is the leading 
cause of death in the world today. With 4.9 million 
tobacco-related deaths per year, no other consumer 
product is as dangerous or kills as many people as 
tobacco (3).
PHYSICAL AND CHEMICAL DATA (4)
Chemical formula: C10H14N2
IUPAC name: 3-[2-(N-methylpyrrolidinyl)]pyridine
Appearance: oily, colourless hygroscopic liquid, with 
characteristic odour, turns brown on exposure to air
Boiling point (decomposes): 247  °C
Density: 1.01 g cm-3
Solubility in water: miscible 
Vapour pressure at 20 °C: 0.006 kPa
Octanol/water partition coefficient as log Pow: 1.2
TOXICOKINETICS
Absorption of nicotine
Nicotine absorption can occur through the oral 
cavity, skin, lung, urinary bladder, and gastrointestinal 
tract (5). Absorption of nicotine across biological 
membranes depends on pH (5). In its ionised state, 
such as in acidic environments, nicotine does not 
rapidly cross membranes. The respiratory absorption 
of nicotine is 60 % to 80 % (6). The rapid absorption of 
nicotine from cigarette smoke through the lung occurs 
because of the huge surface area of the alveoli and 
because of dissolution of nicotine at physiological pH 
(approximately 7.4), which facilitates transfer across 
cell membranes. Absorption through the alveoli is 
also dependent on the nicotine concentration in 
the smoke. Nicotine is poorly absorbed from the 
stomach due to the acidity of the gastric fluid, but 
is well absorbed in the small intestine, which has a 
more alkaline pH and a large surface area (5). Nicotine 
base can be absorbed through the skin, and there 
have been cases of poisoning after skin contact with 
pesticides containing nicotine (7, 8). Likewise, there 
is evidence of cutaneous absorption of and toxicity 
from nicotine in tobacco field workers (6). 
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Metabolism of nicotine
In most people nicotine is 70 % to 80 % metabolised 
to cotinine by C-oxidation. The proposed mechanism 
of conversion of nicotine to cotinine involves 
hydroxylation of nicotine by cytochrome P450-
dependent monooxygenases (CYP) and conversion 
to the corresponding aldehyde and production of 
cotinine by a cytosolic enzyme (5). The enzymes 
involved in the C-oxidation of nicotine have mostly 
been identified. The most important enzyme in 
the C-oxidation of nicotine leading to cotinine 
formation is CYP2A6 (9, 10). Other pathways of 
nicotine metabolism involve formation of nornicotine, 
demethyl cotinine, trans-3-hydroxy-cotinine and δ-(3-
pyridyl)-γ-methylaminobutyric acid, N-oxidation and 
N-methylation of nicotine. The phase II metabolism 
involves N- and O-glucuronidation of nicotine and its 
metabolites (5).
Distribution of nicotine in body tissues
The pattern of tissue uptake, examined in tissues 
of rabbits by measuring concentrations of nicotine 
in various tissues after 24-hr constant i.v. infusion of 
nicotine, showed that spleen, liver, lungs, and brain 
have high affinity for nicotine, whereas the affinity of 
adipose tissue is relatively low (11). Nicotine readily 
crosses the placenta and the foetuses of mothers who 
smoke are exposed to higher nicotine concentrations 
than their mothers (12).
Nicotine excretion
It has been demonstrated that nicotine is excreted 
through urine, faeces, bile, saliva, gastric juice, sweat, 
and breast fluid (13, 14). When 14C-nicotine is given 
to an animal, it has been shown that about 55 % of 
the radioactivity is excreted in the urine. However, only 
1 % of the radioactivity was observed in the form of 
unchanged nicotine. This result demonstrates that 
nicotine is excreted following extensive metabolism. 
Nicotine disappears rapidly from the blood, with a 
half-life of 2 h to 3 h in humans (6). Nicotine and 
cotinine are also detected in the urine of infants whose 
mothers smoke, indicating that exposure of mothers 
to tobacco smoke reaches the infant (15). In another 
study, researchers reported that the daily nicotine 
intake was 18 % higher in persons with increased 
nicotine excretion and concluded that the rate of 
elimination of nicotine affects the rate of consumption 
(16). The rate of nicotine excretion is also influenced 
by the pH of the urine. When the pH of the urine is 
made alkaline, the proportion of uncharged nicotine 
increases and reabsorption of nicotine occurs and as 
a result, less nicotine is excreted (17).
METHOD OF ANALYSIS IN BIOLOGICAL 
SAMPLES
Several biological markers have been proposed 
for nicotine exposure assessment. The most widely 
used markers are nicotine in the urine, hair, saliva and 
plasma; and cotinine, a major nicotine metabolite, 
in the urine, saliva and plasma (18). Urine cotinine 
is currently one of the most widely used biomarkers 
for nicotine exposure, but the main disadvantages 
are inter-individual variability in cotinine excretion 
levels for similar exposures and a relatively short 
half-life (19). Nicotine and cotinine in body fluids 
indicate only recent exposure because of their rapid 
elimination (the half life of cotinine in body fluids is 
about 15 h, compared with 2 h for nicotine) (20). Their 
concentrations from hair, by contrast, can provide 
measures of cumulative, long-term exposure (20). 
A wide variety of methods for the analysis of nicotine 
and cotinine in biological samples have been published: 
gas chromatography coupled by nitrogen-phosphorus 
detector or mass-spectrometer, high-performance 
liquid chromatography, radioimmunoassay and 
enzyme linked immunosorbent assay (21).
TOXICITY DATA AND TOXICITY EVALUATION
General toxicity
Acute toxicity
In experimental animals, the dose of nicotine 
which is lethal to 50 % of the animals (LD50) varies 
widely, depending on the route of administration 
and the species used. The intravenous (i.v.) LD50 
dose of nicotine in mice is 7.1 mg kg-1 body weight 
(22). By direct i.v. administration the LD50 to rats was 
determined to 1 mg kg-1 (23). The intraperitoneal (i.p.) 
LD50 values for nicotine in mice and rats have been 
found to be 5.9 mg kg-1 and 14.6 mg kg-1, respectively 
(22). The oral LD50 dose for nicotine in rats is 50 mg
 kg-1 to 60 mg kg-1 (24). The wide variation in sensitivity 
to the toxic effects of nicotine in rodents appears to 
be genetically determined (25). Dermal acute toxicity 
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(LD50) in rabbits is 140 mg kg
-1 (26). In interpreting 
animal toxicity data it is important to recognise that the 
route of administration is an important determinant of 
toxicity. Rapid i.v. injections result in the highest blood 
and brain concentrations and produce toxicity at the 
lowest doses. In contrast, oral or i.p. administration 
require higher doses to produce toxicity. This is due 
in part to pre-systemic (“first pass”) metabolism of 
nicotine whereby, after absorption into the portal 
venous circulation, nicotine is metabolised by the liver 
before it reaches the systemic venous circulation.
Probable oral lethal dose in humans is less than 
5 mg kg-1 or a taste (less than 7 drops) for a 70 kg 
person (27). It may be assumed that ingestion of 40 
mg to 60 mg of nicotine is lethal to humans (27). 
No inhalation toxicity data are available on which to 
base an immediately dangerous to life or health 
concentration (IDLH) for nicotine. Therefore, the 
revised IDLH for nicotine is 5 mg m-3 based on acute 
oral toxicity data in humans and animals (28).
A number of poisonings and deaths from ingestion 
of nicotine, primarily involving nicotine-containing 
pesticides, have been reported in humans (6). Nicotine 
poisoning produces nausea, vomiting, abdominal 
pain, diarrhoea, headaches, sweating, and pallor. More 
severe poisoning results in dizziness, weakness, and 
confusion, progressing to convulsions, hypotension, 
and coma. Death is usually due to paralysis of 
respiratory muscles and/or central respiratory failure. 
Dermal exposure to nicotine can also lead to poisoning. 
Such exposures have been reported after spilling or 
applying nicotine-containing insecticides on the skin 
or clothes and as a consequence of occupational 
contact with tobacco leaves (6, 8). Acute intoxication 
may occur in children following ingestion of tobacco 
materials. Four children, each of whom ingested two 
cigarettes, developed salivation, vomiting, diarrhoea, 
tachypnoea, tachycardia, and hypertension within 30 
min, followed by depressed respiration and cardiac 
arrhythmia within 40 min and convulsions within 60 
min (29). All recovered and suffered no complication. 
Although ingestions of tobacco are common, deaths 
due to ingestion of tobacco are extremely rare, due 
to early vomiting and first pass metabolism of the 
nicotine that is absorbed.
Long-term toxicity
As attested to in the U.S. Surgeon General’s reports 
since 1964, smoking causes coronary and peripheral 
vascular disease, cancer, chronic obstructive lung 
disease, peptic ulcer disease, and reproductive 
disturbances, including prematurity (30). Nicotine 
may contribute to tobacco-related disease, but direct 
causation has not been determined because nicotine 
is taken up simultaneously with a multitude of other 
potentially harmful substances that occur in tobacco 
smoke and smokeless tobacco. However, particularly 
now that nicotine may be prescribed in the form of 
gum or other delivery systems, the potential health 




Nicotine rapidly crosses the placenta and enters 
the foetus (12). Khan et al. (31) have described 
teratogenic effects of high doses of nicotine, which 
interfered with skeletogenesis in mice and chick 
embryos. In animal studies designed to investigate 
neurotoxic effects, nicotine was found to target 
neurotransmitter receptors in the foetal brain, leading 
to reduced cell proliferation and, consequently, altered 
synaptic activity. Sandberg et al. (32) found that 
prenatal exposure to nicotine (1.5 mg kg-1 per day 
during the last foetal trimester) induced structural 
changes in the lungs of foetal lamb.
On the basis of animal studies, it appears that 
nicotine acts on the respiratory and central nervous 
systems of the foetus and concentrates in maternal 
and foetal blood, amniotic fluid, and breast milk (33). 
Nicotine may have a direct toxic effect on the foetal 
cardiovascular system resulting in reduced blood 
flow (34).
Pregnancy
Exposure to nicotine in rhesus monkeys has 
been shown to decrease tubal motility, which may 
increase the chance of tubal implantation and ectopic 
pregnancy (35). In rats, nicotine caused pregnancy 
failure after dermal application of relatively low levels 
(1.75 mg kg-1 bw per day) throughout gestation (6).
A likely mechanism for the reproductive problems 
in pregnant cigarette smokers is placental insufficiency, 
which is supported by the evidence of placental 
hypoperfusion in cigarette smoking mothers (36). 
Nicotine may have a direct toxic effect on the foetal 
cardiovascular system resulting in reduced blood 
flow (34). Maternal smoking during pregnancy is a 
major risk factor for sudden infant death syndrome 
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(SIDS), with nicotine likely to be the active agent 
(37). Foetal hypoxemia has also been considered as 
a contributory cause of behavioural abnormalities, 
such as hyperactivity, short attention span, lower 
scores on spelling and reading tests, which occurred 
at a higher frequency in children whose mothers had 
smoked throughout pregnancy than in those born to 
nonsmoking mothers (37).
Genotoxicity and carcinogenicity
Studies evaluated the genotoxic potentials of 
nicotine by Salmonella mutagenicity assay and in the 
Chinese hamster ovary sister-chromatid exchange 
(SCE) assay (38). All assays were conducted with 
and without S9 metabolic activation. Nicotine was 
not able to induce mutations or sister chromatid 
exchange in these experimental systems. However, 
opposite results were established in another study 
using Chinese hamster ovary cells (39). Nicotine was 
reported to increase chromosome aberrations and 
sister chromatid exchange frequency in a dose- and 
time-dependent manner in Chinese hamster ovary 
cells, and it was concluded that nicotine acted as 
a clastogen. It was also reported that nicotine was 
genotoxic at the concentrations found in saliva 
achieved during tobacco chewing (39). Nicotine was 
found as a co-carcinogen in animals (27).
Cardiovascular disease
Nicot ine plays an important role in the 
development of cardiovascular disease. It could 
promote atherosclerotic disease by its actions on 
lipid metabolism and coagulation, by haemodynamic 
effects, and/or by causing endothelial injury. Compared 
to nonsmokers, cigarette smokers have elevated 
low-density (LDL) and very-low-density lipoproteins 
(VLDL), as well as reduced high-density lipoprotein 
(HDL) levels, a profile associated with an increased 
risk of atherosclerosis (40). Lipid peroxidation and 
generation of free radicals, increased in smokers, 
are the processes associated with the pathogenesis 
of atherosclerosis. The products of lipid peroxidation 
may cause irreversible damage to the membrane 
structure of the cells. Some studies show that nicotine 
administration to animals results in endothelial 
cell abnormalities and decreases the synthesis of 
prostacyclin (an inhibitor of platelet aggregation) (41). 
Nicotine increases heart rate through the activation 
of the sympathetic nervous system (40).
Pulmonary toxicity
Cigarette smoking is the major cause of chronic 
obstructive lung disease (30). Nicotine, which is 
readily absorbed from the lung and distributed 
to tissue, including bone marrow, increases the 
expression of the elastase gene, leading to increased 
elastase protein concentration per cell, suggesting 
a pathophysiologic mechanism for emphysema 
(42). Inhaled nicotine produces a concentration-
dependent cough and airway obstruction in healthy 
subjects, probably because of stimulation of afferent 
nerve endings in the bronchial mucosa and mediated 
through parasympathetic cholinergic pathways (43).
Immunotoxicity
There is some evidence that nicotine administration 
in vitro can produce changes in immunocytes. 
Although the majority of the above studies suggest 
an in vitro effect of nicotine on immunocytes, little 
direct evidence exists regarding the in vivo action of 
nicotine on the immune system (44). Regarding the 
possible mechanisms that might mediate the effects 
of nicotine on the immune function, some have 
suggested that one consequence of the glucocorticoid 
hypersecretion produced by nicotine exposure, such 
as that experienced by habitual smokers, is the 
suppression of the immune system (45).
Gastrointestinal toxicity
Normally, the gastrointestinal mucosa is protected 
from injury by a layer of mucus and by the secretion of 
bicarbonate by gastric and duodenal epithelial cells to 
neutralize gastric acid. If these protective mechanisms 
are impaired, or if there is an increase in the levels of 
damaging factors, then ulceration may occur. Nicotine 
and other components of cigarette increase the reflux 
of duodenal contents into the stomach and mouth, 
decrease the secretion of pancreatic bicarbonate, 
decrease the production of gastric mucus and 
cytoprotective prostaglandins, and perhaps increase 
the production of free radicals and the release of 
vasopressin, a potent vasoconstrictor (46, 47).
EXPOSURE
Tobacco smoke is the main source of nicotine 
exposure. According to European Community 
Directive 2001/37/EC, nicotine content is limited to a 
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maximum of 1 mg per cigarette from 1 January 2004. 
Seventy five percent or more of nicotine emitted from 
a cigarette is emitted into the air as sidestream smoke, 
which contributes substantially to environmental 
tobacco smoke (ETS). Nicotine in ETS is inhaled 
into the lungs by nonsmokers. The data of Jarvis
et al. (48) on adults attending London hospital are 
an example of estimating daily nicotine intake from 
ETS. Using urine concentrations, the estimated daily 
intake of nicotine by nonsmokers was 100 µg for 
those reporting passive exposure and 20 μg for those 
reporting no exposure to ETS.
As already mentioned, nicotine is present in 
certain human foods, especially plants from the family 
Solanaceae (potatoes, tomatoes, and eggplant) 
(Table 1.).
HAZARDOUS EXPOSURE AND RISK 
ESTIMATION
Human data
A harmful contamination of the air can be reached 
rather quickly on evaporation of this substance at 
20 °C resulting in nausea, vomiting, convulsions, 
abdominal pain, diarrhoea, headache, sweating, 
weakness, dizziness and confusion. Nicotine irritates 
the eyes and the skin and may cause effects on the 
cardiovascular system and central nervous system, 
resulting in convulsions and respiratory failure. 
Exposure far above the observed effect level may result 
in death. The effects of nicotine may be delayed, so 
medical monitoring is indicated. Acute toxic effects 
from nicotine generally result from oral exposure (4). 
Nicotine is highly toxic with nausea occurring from 
exposure to 2 mg to 5 mg and deaths were reported 
in adults from ingested quantities of 40 mg to 60 mg. 
Infants are especially susceptible to nicotine toxicity. 
The ingestion of one or more fresh cigarettes is 
considered potentially toxic.
Chronic toxicity that may be caused by prolonged 
exposure to small doses occurs in smoking (27). 
Maternal smoking during pregnancy is associated 
with increased risk of spontaneous abortion, low 
birth weight and stillbirth (6). Mechanisms include 
the reduction of uteroplacental blood flow and direct 
effects on developing foetal brain. In case-control 
studies, there was no association between spraying 
nicotine and the incidence of multiple myeloma in 
farmers; neither was there a convincing association 
between spraying nicotine and the incidence of 
leukaemia (6).
Workplace level of nicotine in the air due to ETS 
is 20 µg m-3. The dose of nicotine inhaled is equal 
to the product of air concentration and ventilation 
rate. A typical ventilation rate for an adult during 
light activity is 1 m3 per hour. Thus, the intake of 
nicotine would be about 20 µg per hour. About 
71 % of nicotine that is inhaled is absorbed, so the 
systemic dose of nicotine is estimated to be about 
14 µg per hour. Assuming an eight-hour workplace 
exposure, this would be equivalent to 112 µg per day 
(52). Air nicotine levels measured by Hammond et 
al. (53) over nine hours at 11 Massachusetts office 
worksites that allowed smoking, indicated a median 
level of 8.6 µg m-3. The estimated absorption of 
nicotine from this level of exposure over nine hours 
is 55 µg. In office workplaces that banned smoking, 
the median air nicotine level was 0.3 µg m-3. The 
National Institute for Occupational Safety and Health 
(NIOSH) Recommended Exposure Limit (REL) and 
the American Conference of Governmental Industrial 
Hygienists’ (ACGIH) Threshold Limit Value (TLV) for 
nicotine are 500 µg m-3 (27). A model used to derive 
a health-based standard for ETS has shown that an 




content / ng g-1
Reference
Amount of vegetable 
required to obtain 1μg of 
nicotine* / g
Cauliflower 3.8 Domino et al. (49) 263.4
Eggplant 100.0 Castro and Monji (50) 10.0
Potatoes 7.1 Domino et al. (49) 140.4
Green tomatoes 42.8 Castro and Monji (50) 23.4
Red tomatoes 10.7 Sheen (51) 93.5
*One microgram of nicotine is the amount a passive smoker would absorb in about three hours in a room with a minimal amount of tobacco 
smoke.
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eight-hour, time-weighted average exposure to 2.3 
µg m-3 of nicotine would correspond to three lung 
cancer deaths among 10,000 exposed people over a 
working lifetime (54).
Average nicotine daily intake (i. e. absorbed dose) 
from significant ETS plus dietary exposure is about 80 
µg and even a diet rich in nicotine-containing food is 
only 10 % of the total nicotine exposure (55).
RISK EVALUATION
In 2004, The Committee on Updating of 
Occupational Exposure Limits (6) considered the no-
observed-adverse-effect level (NOAEL) of 0.5 mg m-3 
from a two-year inhalation rat study as a starting point 
in deriving a health-based recommended occupational 
exposure limit (HBROEL). The Committee noted that 
the actual NOAEL might be higher since exposure 
was for 20 h a day and only one concentration was 
tested. Since workers are supposed to be exposed for 
maximally eight hours a day, this NOAEL is adjusted, 
resulting in a 1.25 mg m-3. For the extrapolation to 
a HBROEL, the Committee established an overall 
assessment factor of 9. This factor covered intra- 
and interspecies variation. Thus, applying this factor 
of 9 and the preferred-value approach, a health-
based occupational exposure limit of 0.1 mg m-3 
was recommended for nicotine. The Committee 
recommended a health-based occupational exposure 
limit for nicotine of 0.1 mg m-3, as an eight-hour 
time-weighted average (TWA). Because of the high 
skin absorption potential of nicotine, the committee 
advised a skin notation. After the final report was 
published in March 2004, the Health Council received 
comments which were taken into account in deciding 
on revised version published in 2005. The committee 
considered NOAEL of 0.5 mg m-3, implying that 
this two-year inhalation rat study does not provide 
information on the lowest exposure level at which 
adverse effects are becoming manifest. Therefore, 
the committee considered this study inappropriate 
for deriving a health-based occupational exposure 
limit (56). The current occupational exposure limit 
for nicotine in Croatia is 0.5 mg m-3 (57).
The risk of occupational exposure is low if protective 
measures are applied (eye protection in combination 
with breathing protection, protective gloves and 
clothing, and ventilation). The human health risk from 
environmental exposure to nicotine is high because 
nicotine is widespread in the environment through 
tobacco smoke.
It is very important to point out that with intermittent 
dosing, such as practiced by smokers, the total dose 
of nicotine absorbed per day could exceed the toxic 
or even lethal dose of a single injection.
As previously described, food is a source of 
low-level nicotine exposure and for most people it 
represents an insignificant exposure compared with 
exposure to ETS.
CONCLUSION
Tobacco smoke contains more than 3,800 
different compounds. Although all of these substances 
affect exposed humans to some degree, nicotine is 
generally considered to be the primary substance 
responsible for the pharmacological responses to 
smoking. In many countries tobacco smoking is 
recognised as a serious health hazard and a major 
contributing factor to deaths from a number of 
common diseases. Because of that, knowledge of the 
toxicity of nicotine is important to help understand 
tobacco-induced human disease as well as to assess 
the potential risks associated with the therapeutic use 
of nicotine as an aid in quitting smoking. Nicotine 
as a biomarker is very important for quantifying 
human exposure to environmental tobacco smoke 
(ETS) and for predicting potential health risks for 
exposed individuals. Passive smoking is a real and 
significant threat to public health. The first step is 
the promotion of effective measures protecting from 
indoor exposure to tobacco smoke at the workplace, 
in public transport, and other public places.
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Nikotin je alkaloid iz lišæa duhana i glavni sastojak duhanskog dima. U prvom dijelu rada opisana su fizièka i 
kemijska svojstva nikotina, metode odreðivanja nikotina i kotinina, glavnog i specifiènog metabolita nikotina 
u biološkim uzorcima, apsorpcija, raspodjela, biotransformacija i izluèivanje nikotina. Navedeni su podaci 
za akutnu i kroniènu toksiènost nikotina te podaci o zdravstvenim uèincima nikotina na reprodukcijski, 
krvožilni, dišni, gastrointestinalni i imunosni sustav. Opisan je rizik izloženosti ljudi kao posljedica udisanja 
duhanskog dima i uzimanja hrane koja sadržava nikotin. Na kraju je opisano donošenje pravilnika kojim se 
propisuje maksimalno dopuštena koncentracija nikotina u zraku radnih prostorija i prostora, koja prema 
sadašnjem stupnju saznanja ne izaziva ošteæenje zdravlja zaposlenih. 
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